ReNeuron Group plc

("ReNeuron" or the "Company")

Notice of Results

Analyst meeting and Investor presentation

ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, will announce its preliminary results for the year ended 31 March 2022 on Monday 4 July 2022.

Analyst briefing

Iain Ross, Chairman, Catherine Isted, Chief Financial Officer and Dr Randolph Corteling, Vice President of Research will be hosting a briefing for analysts which will take place in the City of London on Monday 4 July 2022 at 13.00 (BST) / 08:00 (ET). A Zoom link will also be available for those unable to attend the meeting in-person.

For more information and to register to attend the meeting in-person or to receive the Zoom link, please email reneuron@walbrookpr.com or call +44 (0)20 7933 8785.

Investor Briefing

Management will also be hosting a live online presentation relating to the preliminary results via the Investor Meet Company platform at 15.00 on Monday 4 July. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here:

https://www.investormeetcompany.com/reneuron-group-plc/register-investor

Investors who already follow ReNeuron on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function.  Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

ENDS

Contacts:

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

The Company has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-licence both these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com